Loading…

The Sorin Freedom SOLO stentless tissue valve: early outcomes after aortic valve replacement

We prospectively evaluated the hemodynamic performance of the SORIN Freedom SOLO aortic bioprosthesis, a stentless bovine pericardial valve designed for supra-annular implantation. Forty patients (mean age, 71.68 ± 5.25 yr; 29 men) with severe aortic stenosis underwent aortic valve replacement from...

Full description

Saved in:
Bibliographic Details
Published in:Texas Heart Institute journal 2013, Vol.40 (1), p.50-55
Main Authors: Altintas, Garip, Diken, Adem Ilkay, Hanedan, Onur, Yurdakok, Okan, Ozyalcin, Sertan, Kucuker, Seref Alp, Ozatik, Mehmet Ali
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 55
container_issue 1
container_start_page 50
container_title Texas Heart Institute journal
container_volume 40
creator Altintas, Garip
Diken, Adem Ilkay
Hanedan, Onur
Yurdakok, Okan
Ozyalcin, Sertan
Kucuker, Seref Alp
Ozatik, Mehmet Ali
description We prospectively evaluated the hemodynamic performance of the SORIN Freedom SOLO aortic bioprosthesis, a stentless bovine pericardial valve designed for supra-annular implantation. Forty patients (mean age, 71.68 ± 5.25 yr; 29 men) with severe aortic stenosis underwent aortic valve replacement from January 2008 through August 2009. Patients were evaluated by transthoracic echocardiography and clinical examination, both preoperatively and again at 6 and 24 postoperative months. Peak and mean transvalvular gradients, end-diastolic and end-systolic diameters, interventricular septal and posterior wall thicknesses, indexed volumes of ventricular mass, degrees of aortic regurgitation, and left ventricular ejection fractions were calculated echocardiographically. The valves were implanted with single polypropylene sutures. In the early postoperative period, 1 patient (2.5%) died of multiorgan failure. The mean aortic cross-clamp time was 86.05 ± 34.2 min. Echocardiographic peak gradients were 84.54 ± 16.85 mmHg (preoperative), 29.59 ± 6.27 mmHg (6 mo postoperative), and 24.33 ± 4.67 mmHg (24 mo postoperative) (P < 0.001); left ventricular mass indices were 176.26 ± 39.98 g/m(2) (preoperative), 139.21 ± 30.1 (6 mo postoperative), and 120.51 ± 23.88 g/m(2) (24 mo postoperative) (P < 0.001). During follow-up, the maximum aortic insufficiency recorded was trace, and no valve dysfunctions were observed. Temporary thrombocytopenia was documented in all patients during early postoperative follow-up (lowest level at day 3); recovery to preoperative levels occurred by day 10. The Freedom SOLO aortic bioprosthesis is an easy-to-implant valve with excellent hemodynamic performance. The thrombocytopenia appears to be a transient laboratory finding.
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3568268</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1315627660</sourcerecordid><originalsourceid>FETCH-LOGICAL-p266t-1eddf7330b9ae24f7c83bfdfd91ac108bee981a425f90697d0f00bb43f445e9b3</originalsourceid><addsrcrecordid>eNpVkF1LwzAUhoMobk7_guTSm0I-2rTxQpDhVBjsYvNOKEl74ippU5O0sH9vYVP06sA573keeM_QnGZMJCIn7BzNSc5Jwniaz9BVCJ-EEM4ou0SzaSeEZHKO3nd7wFvnmw6vPEDtWrzdrDc4ROiihRBwbEIYAI_KjnCPQXl7wG6IlWshYGUieKycj011jGAPvVUVtNP_Nbowyga4Oc0Fels97ZYvyXrz_Lp8XCc9EyImFOra5JwTLRWw1ORVwbWpTS2pqigpNIAsqEpZZiQRMq-JIUTrlJs0zUBqvkAPR24_6BbqalJ7ZcveN63yh9Kppvx_6Zp9-eHGkmeiYKKYAHcngHdfA4RYtk2owFrVgRtCSTnNBMuFIFP09q_rV_JTKf8G9CB2Pg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1315627660</pqid></control><display><type>article</type><title>The Sorin Freedom SOLO stentless tissue valve: early outcomes after aortic valve replacement</title><source>PubMed Central</source><creator>Altintas, Garip ; Diken, Adem Ilkay ; Hanedan, Onur ; Yurdakok, Okan ; Ozyalcin, Sertan ; Kucuker, Seref Alp ; Ozatik, Mehmet Ali</creator><creatorcontrib>Altintas, Garip ; Diken, Adem Ilkay ; Hanedan, Onur ; Yurdakok, Okan ; Ozyalcin, Sertan ; Kucuker, Seref Alp ; Ozatik, Mehmet Ali</creatorcontrib><description>We prospectively evaluated the hemodynamic performance of the SORIN Freedom SOLO aortic bioprosthesis, a stentless bovine pericardial valve designed for supra-annular implantation. Forty patients (mean age, 71.68 ± 5.25 yr; 29 men) with severe aortic stenosis underwent aortic valve replacement from January 2008 through August 2009. Patients were evaluated by transthoracic echocardiography and clinical examination, both preoperatively and again at 6 and 24 postoperative months. Peak and mean transvalvular gradients, end-diastolic and end-systolic diameters, interventricular septal and posterior wall thicknesses, indexed volumes of ventricular mass, degrees of aortic regurgitation, and left ventricular ejection fractions were calculated echocardiographically. The valves were implanted with single polypropylene sutures. In the early postoperative period, 1 patient (2.5%) died of multiorgan failure. The mean aortic cross-clamp time was 86.05 ± 34.2 min. Echocardiographic peak gradients were 84.54 ± 16.85 mmHg (preoperative), 29.59 ± 6.27 mmHg (6 mo postoperative), and 24.33 ± 4.67 mmHg (24 mo postoperative) (P &lt; 0.001); left ventricular mass indices were 176.26 ± 39.98 g/m(2) (preoperative), 139.21 ± 30.1 (6 mo postoperative), and 120.51 ± 23.88 g/m(2) (24 mo postoperative) (P &lt; 0.001). During follow-up, the maximum aortic insufficiency recorded was trace, and no valve dysfunctions were observed. Temporary thrombocytopenia was documented in all patients during early postoperative follow-up (lowest level at day 3); recovery to preoperative levels occurred by day 10. The Freedom SOLO aortic bioprosthesis is an easy-to-implant valve with excellent hemodynamic performance. The thrombocytopenia appears to be a transient laboratory finding.</description><identifier>ISSN: 0730-2347</identifier><identifier>EISSN: 1526-6702</identifier><identifier>PMID: 23466929</identifier><language>eng</language><publisher>United States: Texas Heart Institute</publisher><subject>Aged ; Aged, 80 and over ; Aortic Valve Stenosis - diagnosis ; Aortic Valve Stenosis - mortality ; Aortic Valve Stenosis - physiopathology ; Aortic Valve Stenosis - surgery ; Bioprosthesis ; Clinical Investigation ; Female ; Heart Valve Prosthesis ; Heart Valve Prosthesis Implantation - adverse effects ; Heart Valve Prosthesis Implantation - instrumentation ; Heart Valve Prosthesis Implantation - mortality ; Hemodynamics ; Humans ; Male ; Middle Aged ; Multiple Organ Failure - mortality ; Prospective Studies ; Prosthesis Design ; Severity of Illness Index ; Thrombocytopenia - etiology ; Time Factors ; Treatment Outcome</subject><ispartof>Texas Heart Institute journal, 2013, Vol.40 (1), p.50-55</ispartof><rights>2013 by the Texas Heart® Institute, Houston</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3568268/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3568268/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,4009,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23466929$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Altintas, Garip</creatorcontrib><creatorcontrib>Diken, Adem Ilkay</creatorcontrib><creatorcontrib>Hanedan, Onur</creatorcontrib><creatorcontrib>Yurdakok, Okan</creatorcontrib><creatorcontrib>Ozyalcin, Sertan</creatorcontrib><creatorcontrib>Kucuker, Seref Alp</creatorcontrib><creatorcontrib>Ozatik, Mehmet Ali</creatorcontrib><title>The Sorin Freedom SOLO stentless tissue valve: early outcomes after aortic valve replacement</title><title>Texas Heart Institute journal</title><addtitle>Tex Heart Inst J</addtitle><description>We prospectively evaluated the hemodynamic performance of the SORIN Freedom SOLO aortic bioprosthesis, a stentless bovine pericardial valve designed for supra-annular implantation. Forty patients (mean age, 71.68 ± 5.25 yr; 29 men) with severe aortic stenosis underwent aortic valve replacement from January 2008 through August 2009. Patients were evaluated by transthoracic echocardiography and clinical examination, both preoperatively and again at 6 and 24 postoperative months. Peak and mean transvalvular gradients, end-diastolic and end-systolic diameters, interventricular septal and posterior wall thicknesses, indexed volumes of ventricular mass, degrees of aortic regurgitation, and left ventricular ejection fractions were calculated echocardiographically. The valves were implanted with single polypropylene sutures. In the early postoperative period, 1 patient (2.5%) died of multiorgan failure. The mean aortic cross-clamp time was 86.05 ± 34.2 min. Echocardiographic peak gradients were 84.54 ± 16.85 mmHg (preoperative), 29.59 ± 6.27 mmHg (6 mo postoperative), and 24.33 ± 4.67 mmHg (24 mo postoperative) (P &lt; 0.001); left ventricular mass indices were 176.26 ± 39.98 g/m(2) (preoperative), 139.21 ± 30.1 (6 mo postoperative), and 120.51 ± 23.88 g/m(2) (24 mo postoperative) (P &lt; 0.001). During follow-up, the maximum aortic insufficiency recorded was trace, and no valve dysfunctions were observed. Temporary thrombocytopenia was documented in all patients during early postoperative follow-up (lowest level at day 3); recovery to preoperative levels occurred by day 10. The Freedom SOLO aortic bioprosthesis is an easy-to-implant valve with excellent hemodynamic performance. The thrombocytopenia appears to be a transient laboratory finding.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Aortic Valve Stenosis - diagnosis</subject><subject>Aortic Valve Stenosis - mortality</subject><subject>Aortic Valve Stenosis - physiopathology</subject><subject>Aortic Valve Stenosis - surgery</subject><subject>Bioprosthesis</subject><subject>Clinical Investigation</subject><subject>Female</subject><subject>Heart Valve Prosthesis</subject><subject>Heart Valve Prosthesis Implantation - adverse effects</subject><subject>Heart Valve Prosthesis Implantation - instrumentation</subject><subject>Heart Valve Prosthesis Implantation - mortality</subject><subject>Hemodynamics</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multiple Organ Failure - mortality</subject><subject>Prospective Studies</subject><subject>Prosthesis Design</subject><subject>Severity of Illness Index</subject><subject>Thrombocytopenia - etiology</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>0730-2347</issn><issn>1526-6702</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNpVkF1LwzAUhoMobk7_guTSm0I-2rTxQpDhVBjsYvNOKEl74ippU5O0sH9vYVP06sA573keeM_QnGZMJCIn7BzNSc5Jwniaz9BVCJ-EEM4ou0SzaSeEZHKO3nd7wFvnmw6vPEDtWrzdrDc4ROiihRBwbEIYAI_KjnCPQXl7wG6IlWshYGUieKycj011jGAPvVUVtNP_Nbowyga4Oc0Fels97ZYvyXrz_Lp8XCc9EyImFOra5JwTLRWw1ORVwbWpTS2pqigpNIAsqEpZZiQRMq-JIUTrlJs0zUBqvkAPR24_6BbqalJ7ZcveN63yh9Kppvx_6Zp9-eHGkmeiYKKYAHcngHdfA4RYtk2owFrVgRtCSTnNBMuFIFP09q_rV_JTKf8G9CB2Pg</recordid><startdate>2013</startdate><enddate>2013</enddate><creator>Altintas, Garip</creator><creator>Diken, Adem Ilkay</creator><creator>Hanedan, Onur</creator><creator>Yurdakok, Okan</creator><creator>Ozyalcin, Sertan</creator><creator>Kucuker, Seref Alp</creator><creator>Ozatik, Mehmet Ali</creator><general>Texas Heart Institute</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>2013</creationdate><title>The Sorin Freedom SOLO stentless tissue valve: early outcomes after aortic valve replacement</title><author>Altintas, Garip ; Diken, Adem Ilkay ; Hanedan, Onur ; Yurdakok, Okan ; Ozyalcin, Sertan ; Kucuker, Seref Alp ; Ozatik, Mehmet Ali</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p266t-1eddf7330b9ae24f7c83bfdfd91ac108bee981a425f90697d0f00bb43f445e9b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Aortic Valve Stenosis - diagnosis</topic><topic>Aortic Valve Stenosis - mortality</topic><topic>Aortic Valve Stenosis - physiopathology</topic><topic>Aortic Valve Stenosis - surgery</topic><topic>Bioprosthesis</topic><topic>Clinical Investigation</topic><topic>Female</topic><topic>Heart Valve Prosthesis</topic><topic>Heart Valve Prosthesis Implantation - adverse effects</topic><topic>Heart Valve Prosthesis Implantation - instrumentation</topic><topic>Heart Valve Prosthesis Implantation - mortality</topic><topic>Hemodynamics</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multiple Organ Failure - mortality</topic><topic>Prospective Studies</topic><topic>Prosthesis Design</topic><topic>Severity of Illness Index</topic><topic>Thrombocytopenia - etiology</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Altintas, Garip</creatorcontrib><creatorcontrib>Diken, Adem Ilkay</creatorcontrib><creatorcontrib>Hanedan, Onur</creatorcontrib><creatorcontrib>Yurdakok, Okan</creatorcontrib><creatorcontrib>Ozyalcin, Sertan</creatorcontrib><creatorcontrib>Kucuker, Seref Alp</creatorcontrib><creatorcontrib>Ozatik, Mehmet Ali</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Texas Heart Institute journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Altintas, Garip</au><au>Diken, Adem Ilkay</au><au>Hanedan, Onur</au><au>Yurdakok, Okan</au><au>Ozyalcin, Sertan</au><au>Kucuker, Seref Alp</au><au>Ozatik, Mehmet Ali</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Sorin Freedom SOLO stentless tissue valve: early outcomes after aortic valve replacement</atitle><jtitle>Texas Heart Institute journal</jtitle><addtitle>Tex Heart Inst J</addtitle><date>2013</date><risdate>2013</risdate><volume>40</volume><issue>1</issue><spage>50</spage><epage>55</epage><pages>50-55</pages><issn>0730-2347</issn><eissn>1526-6702</eissn><abstract>We prospectively evaluated the hemodynamic performance of the SORIN Freedom SOLO aortic bioprosthesis, a stentless bovine pericardial valve designed for supra-annular implantation. Forty patients (mean age, 71.68 ± 5.25 yr; 29 men) with severe aortic stenosis underwent aortic valve replacement from January 2008 through August 2009. Patients were evaluated by transthoracic echocardiography and clinical examination, both preoperatively and again at 6 and 24 postoperative months. Peak and mean transvalvular gradients, end-diastolic and end-systolic diameters, interventricular septal and posterior wall thicknesses, indexed volumes of ventricular mass, degrees of aortic regurgitation, and left ventricular ejection fractions were calculated echocardiographically. The valves were implanted with single polypropylene sutures. In the early postoperative period, 1 patient (2.5%) died of multiorgan failure. The mean aortic cross-clamp time was 86.05 ± 34.2 min. Echocardiographic peak gradients were 84.54 ± 16.85 mmHg (preoperative), 29.59 ± 6.27 mmHg (6 mo postoperative), and 24.33 ± 4.67 mmHg (24 mo postoperative) (P &lt; 0.001); left ventricular mass indices were 176.26 ± 39.98 g/m(2) (preoperative), 139.21 ± 30.1 (6 mo postoperative), and 120.51 ± 23.88 g/m(2) (24 mo postoperative) (P &lt; 0.001). During follow-up, the maximum aortic insufficiency recorded was trace, and no valve dysfunctions were observed. Temporary thrombocytopenia was documented in all patients during early postoperative follow-up (lowest level at day 3); recovery to preoperative levels occurred by day 10. The Freedom SOLO aortic bioprosthesis is an easy-to-implant valve with excellent hemodynamic performance. The thrombocytopenia appears to be a transient laboratory finding.</abstract><cop>United States</cop><pub>Texas Heart Institute</pub><pmid>23466929</pmid><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0730-2347
ispartof Texas Heart Institute journal, 2013, Vol.40 (1), p.50-55
issn 0730-2347
1526-6702
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3568268
source PubMed Central
subjects Aged
Aged, 80 and over
Aortic Valve Stenosis - diagnosis
Aortic Valve Stenosis - mortality
Aortic Valve Stenosis - physiopathology
Aortic Valve Stenosis - surgery
Bioprosthesis
Clinical Investigation
Female
Heart Valve Prosthesis
Heart Valve Prosthesis Implantation - adverse effects
Heart Valve Prosthesis Implantation - instrumentation
Heart Valve Prosthesis Implantation - mortality
Hemodynamics
Humans
Male
Middle Aged
Multiple Organ Failure - mortality
Prospective Studies
Prosthesis Design
Severity of Illness Index
Thrombocytopenia - etiology
Time Factors
Treatment Outcome
title The Sorin Freedom SOLO stentless tissue valve: early outcomes after aortic valve replacement
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T00%3A34%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Sorin%20Freedom%20SOLO%20stentless%20tissue%20valve:%20early%20outcomes%20after%20aortic%20valve%20replacement&rft.jtitle=Texas%20Heart%20Institute%20journal&rft.au=Altintas,%20Garip&rft.date=2013&rft.volume=40&rft.issue=1&rft.spage=50&rft.epage=55&rft.pages=50-55&rft.issn=0730-2347&rft.eissn=1526-6702&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1315627660%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p266t-1eddf7330b9ae24f7c83bfdfd91ac108bee981a425f90697d0f00bb43f445e9b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1315627660&rft_id=info:pmid/23466929&rfr_iscdi=true